Technology in Cancer Research & Treatment最新文献_第9页

Orosomucoid 1 is a Potential Prognostic Biomarker for Uterine Sarcoma. Orosomucoid 1是子宫肉瘤潜在的预后生物标志物。

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-05-19 DOI: 10.1177/15330338251343487

Dan Yuan, Yue Huang, Ying Cai, Chi Zhang, Jin-Jing Wang, Jian-Guo Zhou

{"title":"Orosomucoid 1 is a Potential Prognostic Biomarker for Uterine Sarcoma.","authors":"Dan Yuan, Yue Huang, Ying Cai, Chi Zhang, Jin-Jing Wang, Jian-Guo Zhou","doi":"10.1177/15330338251343487","DOIUrl":"10.1177/15330338251343487","url":null,"abstract":"IntroductionUterine sarcoma (US) is a rare tumor characterized by high aggressiveness, a tendency for recurrence and distant metastasis, and an extremely poor prognosis. In this study, we evaluated the expression of Orosomucoid 1 (ORM1) in different subtypes of US and the relationship between survival rates and clinicopathological features.MethodA retrospective study was conducted on 50 cases diagnosed with US in our hospital from 2011 to 2023. Immunohistochemistry (IHC) was used to detect the expression levels of ORM1 in different subtypes of US.The chi-square test and Kaplan-Meier survival analysis were used to analyze the relationship between ORM1 expression and clinical parameters as well as prognosis. Cox analysis was employed to evaluate the relationships between prognosis and clinical parameters in US.ResultCompared to normal proliferative endometrial tissue (NPE), the expression of ORM1 was downregulated in low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS) (P < .001,P < .001,and P < .001, respectively). Compared to normal uterine smooth muscle tissue (UNSM), the expression of ORM1 was upregulated in leiomyosarcoma (LMS) (P = .006). High ORM1 expression levels in US patients were associated with poor overall survival (OS) and progression-free survival (PFS) (P = .027 and P = .005, respectively). Multivariate COX analysis revealed that tumor stage and ORM1 expression are independent prognostic factors for US patients.ConclusionORM1 is expressed at low levels in ESS and at high levels in LMS. ORM1 potentially serve as a novel biomarker for the diagnosis, classification, and prognosis of US.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251343487"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Learning Reimagined: AI's Role in Advancing Education of Cancer Research and Treatment Technology. 重新想象的学习：人工智能在推进癌症研究和治疗技术教育中的作用。

IF 2.8 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-09-16 DOI: 10.1177/15330338251378314

Maria F Chan, Dongxu Wang

{"title":"Learning Reimagined: AI's Role in Advancing Education of Cancer Research and Treatment Technology.","authors":"Maria F Chan, Dongxu Wang","doi":"10.1177/15330338251378314","DOIUrl":"10.1177/15330338251378314","url":null,"abstract":"Visual learning, through graphics, diagrams, and other visual tools, has been shown to significantly enhance information retention, with studies indicating that up to 83% of learning is visual. In the field of radiation oncology, where continuous education is critical to the safe and effective treatment of cancer, the complexity and text-heavy nature of traditional resources can pose barriers to effective learning. This editorial examines the transformative potential of generative artificial intelligence (AI) in supporting cancer care professionals by enhancing comprehension of radiation oncology documents through tailored, visual learning modules. Using the AAPM TG-100 report \"Application of risk analysis methods to radiation therapy quality management\" as a proof of concept, the authors first developed web-based infographics manually and then demonstrated how AI tools such as ChatGPT, ClickUp, and NotebookLM dramatically expedite the process. These tools not only automate the creation of high-quality visuals but also support personalized and multimodal learning, including AI-generated podcasts for auditory learners. By making complex oncology-specific content more accessible, AI empowers radiation oncology clinicians and trainees to better understand, implement, and innovate in cancer treatment.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251378314"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FTIR Spectroscopy Analysis of Bound Water in Dried Saliva Samples: Differentiation of Smoking and Non-Smoking Groups and Implications for Oral Cancer Risk. 干燥唾液样本中结合水的FTIR光谱分析：吸烟和非吸烟组的区分及其对口腔癌风险的影响。

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-05-19 DOI: 10.1177/15330338251317304

Maria Clara Coelho Ferreira, Vitórya Carvalho Pádua de Magalhães, Thayná Melo de Lima Morais, Felipe Peralta, Pedro Arthur Augusto Castro, Denise Maria Zezell, Marcelo Saito Nogueira, Luis Felipe Cs Carvalho

{"title":"FTIR Spectroscopy Analysis of Bound Water in Dried Saliva Samples: Differentiation of Smoking and Non-Smoking Groups and Implications for Oral Cancer Risk.","authors":"Maria Clara Coelho Ferreira, Vitórya Carvalho Pádua de Magalhães, Thayná Melo de Lima Morais, Felipe Peralta, Pedro Arthur Augusto Castro, Denise Maria Zezell, Marcelo Saito Nogueira, Luis Felipe Cs Carvalho","doi":"10.1177/15330338251317304","DOIUrl":"10.1177/15330338251317304","url":null,"abstract":"Background: According to the WHO, oral cancer is the thirteenth most common cancer worldwide, with tobacco use being one of the primary causes of oral cancer. This study aimed to characterize and differentiate the saliva and bound water using FTIR spectroscopy in smoking and non-smoking individuals. Materials and Methods: This prospective observational study analyzed dried saliva samples from control, smoking, and occasional smoking groups using an attenuated total reflectance Fourier Transform Infrared (ATR-FTIR) spectrometer. The high wavenumber spectral region of 2800-3600 cm-¹ was selected for analysis. Results: The results indicate that standard variance normalization (SNV) reduced intragroup variability and highlighted differences in smokers' spectra within the 3250-3500 cm-¹ region, associated with the absorption of water bound to saliva molecules. Cubic SVM models using SNV spectra demonstrated higher classification accuracy between groups, achieving 15.6% greater sensitivity and 1.3% lower specificity compared to models based on the second-order derivative. RUSBoosted Trees addressed data imbalances, enhancing both sensitivity and specificity. The study suggests that spectral changes may reflect salivary biochemistry linked to smoking and potentially to oral cancer risk. Conclusions: We conclude that differentiation between normal individuals and smokers can be achieved using high wavenumber FTIR spectral analysis. Additionally, we demonstrate the relationship between bound water molecules and salivary biomolecules in control, smoking, and occasional smoking groups. This technique has potential applications in elucidating OH vibrations within biological systems.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251317304"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MRI Radiomics-Based Prediction of Occult Sentinel Lymph Node Metastasis and D2-40 Expression in Breast Cancer. 基于MRI放射学预测乳腺癌隐匿前哨淋巴结转移和D2-40表达。

IF 2.8 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-10-15 DOI: 10.1177/15330338251386676

Mingming Chen, Chen Wang, Qiyue Zhang, Zhongyuan Li, Peiji Song, Aimei Ouyang

{"title":"MRI Radiomics-Based Prediction of Occult Sentinel Lymph Node Metastasis and D2-40 Expression in Breast Cancer.","authors":"Mingming Chen, Chen Wang, Qiyue Zhang, Zhongyuan Li, Peiji Song, Aimei Ouyang","doi":"10.1177/15330338251386676","DOIUrl":"10.1177/15330338251386676","url":null,"abstract":"IntroductionPatients with Magnetic Resonance Imaging (MRI) axillary lymph node (ALN) negative in breast cancer may still have occult sentinel lymph node (SLN) metastases, which can influence clinical treatment strategies. This study aimed to develop an MRI-based radiomics model for predicting occult SLN metastases and D2-40 expression, and to investigate the intrinsic associations between D2-40 expression, SLN status, and related radiomics features.MethodsThis retrospective study included 141 MRI-diagnosed ALN-negative breast cancer patients from Center 1, randomly divided into training (n = 98) and validation (n = 43) sets (7:3 ratio). An independent external validation cohort (n = 40) from Centers 1 + 2 was established for model validation. Three logistic regression models were developed: (1) a clinical model, (2) a radiomics model, and (3) a clinic-radiomics nomogram, which predict SLN metastasis (Model 1) and D2-40 expression (Model 2). In addition, the correlation between D2-40 expression and SLN status was analyzed in this study using chi-square test. And the feature correlation between SLN radiomics model and D2-40 radiomics model and the strength of association between D2-40 and Model 1 features were assessed by Spearman and Pearson correlation analysis, respectively.ResultsThe nomogram outperformed the other models in both Model 1 (AUC: 0.821 validation/0.746 external) and Model 2 (AUC: 0.810 validation/0.645 external). D2-40 correlated with SLN status (P < .001). There were feature correlations between Model 1 and Model 2 features (Spearman) and between D2-40 and Model 1 features (Pearson).ConclusionsMRI-based radiomics features were effective in predicting occult SLN metastasis and D2-40 expression status in MRI ALN-negative breast cancers. An association was identified between D2-40 expression and SLN status, along with the corresponding radiomics features.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251386676"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145303522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction: Potential Molecular Mechanisms of AURKB in the Oncogenesis and Progression of Osteosarcoma Cells: A Label-Free Quantitative Proteomics Analysis. 撤回：AURKB在骨肉瘤细胞的肿瘤发生和发展中的潜在分子机制：一种无标记的定量蛋白质组学分析。

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-03-25 DOI: 10.1177/15330338251321913

引用次数: 0

Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor. 双特异性c-Met/PD-1 CAR-T细胞对实体瘤的治疗效果增强

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-04-22 DOI: 10.1177/15330338251336850

HuanRan Yang, YanJun Zhang, YanQiu Li, Shang Peng, Ran An, NaNa Du, JiaWei Cao, Fei Chu, JingTing Min

{"title":"Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.","authors":"HuanRan Yang, YanJun Zhang, YanQiu Li, Shang Peng, Ran An, NaNa Du, JiaWei Cao, Fei Chu, JingTing Min","doi":"10.1177/15330338251336850","DOIUrl":"https://doi.org/10.1177/15330338251336850","url":null,"abstract":"ObjectiveTo evaluate the killing effect of c-Met CAR-T on tumor cells with different degrees of c-Met expression. It was demonstrated that CAR-T autocrine PD-1 antibody could alleviate immune checkpoint inhibition and enhance the anti-tumor effect of T cells.MethodsThe specificity and clinical significance of c-Met and PD-L1 expression in various solid tumors were verified by bioinformatics analysis. c-Met specific CAR-T and c-Met specific CAR-T secreted by PD-L1 were synthesized, and c-Met CAR-T and c-Met/PD-1 CAR-T were prepared by constructing lentivirus. Flow cytometry was used to verify the positive rate and cell population of CAR-T, western blot was used to verify the secretion of PD-1 antibody, and cck-8 was used to detect the proliferation of CAR-T in tumor cells with different c-Met expression. LDH and ELISA further evaluated the antitumor effects of c-Met CAR-T and c-Met/PD-1 CAR-T in vitro.Resultsc-Met and PD-L1 were expressed in pancreatic cancer, ovarian cancer, esophageal cancer, bladder cancer, glioma and other tumors, and were associated with a variety of immune cell infiltration. Tumor cells with high expression of c-Met can strongly stimulate the proliferation of c-Met CAR-T, and c-Met CAR-T has strong cell lysis ability on tumor cells with high expression of c-Met. Autocrine PD-1 antibody can significantly improve the activity of c-Met CAR T cells, tumor lysis ability and cytokine secretion level.ConclusionThe antitumor activity of c-Met CAR-T is positively correlated with the expression of c-Met. c-Met CAR-T secreted by PD-1 showed enhanced antitumor function in solid tumor treatment.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251336850"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer. 探讨循环肿瘤DNA对早期结肠癌患者预后的预测价值。

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 DOI: 10.1177/15330338251317094

Rami Yanes, Turcin Saridogan, Vikram Gorantla, Abigail Overacre, Ronan W Hsieh, James Celebrezze, Tara Magge, Meghana Singhi, Anwaar Saeed, Amer H Zureikat, Arvind N Dasari, Ibrahim Halil Sahin

{"title":"Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer.","authors":"Rami Yanes, Turcin Saridogan, Vikram Gorantla, Abigail Overacre, Ronan W Hsieh, James Celebrezze, Tara Magge, Meghana Singhi, Anwaar Saeed, Amer H Zureikat, Arvind N Dasari, Ibrahim Halil Sahin","doi":"10.1177/15330338251317094","DOIUrl":"10.1177/15330338251317094","url":null,"abstract":"The management of early-stage colon cancer involves surgical resection of the primary tumor with or without chemotherapy, depending on pathological staging. The benefit of adjuvant chemotherapy for stage II and III colon cancer is approximately 5% and 15%, indicating the need for optimization for risk stratification and patient selection. Several studies have revealed that current clinicopathological factors lack precision. Circulating tumor DNA (ctDNA) is cell-free DNA originating from cancer cells and can be detected even in the absence of radiologically detectable disease among patients with colon cancer. Recent cohort studies revealed that ctDNA is one of the most significant prognostic factors for patients with early-stage colon cancer, surpassing pathological and clinical risk factors. Prospective cohort studies also suggest there may be a predictive role for ctDNA on the decision for consideration of adjuvant therapy. Currently, randomized clinical trials are enrolling to better define this role. In this review article, we review recent literature on ctDNA and its role in patients with colon cancer. We also elaborate on the future clinical utility of ctDNA in clinical practice and the unmet need for research to optimize currently available ctDNA assays.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251317094"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Dosimetry and Biological Risk Assessment of Lung Oligometastasis SBRT: VMAT, Helical Tomotherapy, and CyberKnife. 肺少转移的比较剂量学和生物学风险评估SBRT: VMAT，螺旋断层治疗和射波刀。

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-03-28 DOI: 10.1177/15330338251330781

Zhenjiong Shen, Mingyuan Pan, Lan Sun, Aihui Feng, Yanhua Duan, Hengle Gu, Yan Shao, Hua Chen, Hao Wang, Ying Huang, Zhiyong Xu

{"title":"Comparative Dosimetry and Biological Risk Assessment of Lung Oligometastasis SBRT: VMAT, Helical Tomotherapy, and CyberKnife.","authors":"Zhenjiong Shen, Mingyuan Pan, Lan Sun, Aihui Feng, Yanhua Duan, Hengle Gu, Yan Shao, Hua Chen, Hao Wang, Ying Huang, Zhiyong Xu","doi":"10.1177/15330338251330781","DOIUrl":"10.1177/15330338251330781","url":null,"abstract":"PurposeTo compare the dosimetry and biological risk of volumetric modulated arc therapy (VMAT), helical tomotherapy (HT) and cyberKnife (CK) in the treatment of lung oligometastases.Methods and materialsThis retrospective study included a cohort of 21 lung oligometastasis patients, each with 2 or 3 lesions, who had previously undergone stereotactic body radiation therapy (SBRT). VMAT, HT and CK plans were made for each patient. The dose distribution of planning target volume (PTV) and organs at risk (OARs) were evaluated. Three biological risks were evaluated, namely radiation pneumonitis (RP), coronary artery disease (CAD) and congestive heart failure (CHF). Monitor Units (MUs) and beam-on-time were also recorded.ResultsAll techniques were able to produce clinically deliverable plans. The expected biological risks for VMAT plans, CK plans, and HT plans were 6.69%, 5.05%, 5.88% for RP, 1.20%, 1.15%, and 1.17% for CAD, 1.26%, 1.19%, and 1.22% for CHF. The expected risks of RP were slightly lower in CK plans compared to VMAT and HT plans (p < 0.001), with VMAT plans showing the highest expected risks. For central lung cancer, the expected CAD risks of CK and HT plans were lower than those of VMAT plans (p < 0.05). The delivery efficiency of VMAT plans was significantly higher than that of CK plans and HT plans.ConclusionsAll three techniques, VMAT, HT, and CK, meet the therapeutic requirements for target coverage and dose constraints for OARs. Although there are statistical differences, the difference between the expected risk values of RP and CAD is very small, so the clinical manifestations may not show differences.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251330781"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine Learning Model Integrating CT Radiomics of the Lung to Predict Checkpoint Inhibitor Pneumonitis in Patients with Advanced Cancer. 整合肺部CT放射组学的机器学习模型预测晚期癌症患者的检查点抑制剂肺炎。

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-05-23 DOI: 10.1177/15330338251344004

François Cousin, Thomas Louis, Pierre Frères, Julien Guiot, Mariaelena Occhipinti, Fabio Bottari, Wim Vos, Roland Hustinx

{"title":"Machine Learning Model Integrating CT Radiomics of the Lung to Predict Checkpoint Inhibitor Pneumonitis in Patients with Advanced Cancer.","authors":"François Cousin, Thomas Louis, Pierre Frères, Julien Guiot, Mariaelena Occhipinti, Fabio Bottari, Wim Vos, Roland Hustinx","doi":"10.1177/15330338251344004","DOIUrl":"10.1177/15330338251344004","url":null,"abstract":"ObjectiveCheckpoint inhibitor pneumonitis (CIP) is a potentially life-threatening immune-related adverse event. Efficient strategies to select patients at risk are still required. The aim of our study was to assess the utility of a machine learning model, integrating pre-treatment CT lung radiomics features with clinical data, to predict patients at risk of developing CIP.MethodsIn this retrospective study, 116 patients with varied malignancies treated with immune checkpoint inhibitors (ICIs) were included. In this cohort, 35 patients presented with CIP and 81 patients did not. Each lung and its lobes were segmented on pre-treatment CT scans to perform a handcrafted radiomic analysis. Radiomic features were associated with clinical parameters to build generalized linear (GLM) and random forest (RF) models, to predict occurrence of CIP. The models were fine-tuned, validated and tested using a nested 5-fold cross-validation method.ResultsThe RF models combining radiomic and clinical features showed the best performances with an area under the ROC curve (AUC) of 0.75 (95%CI:0.62-0.88) on the test set. The most accurate clinical model was a RF model and achieved an AUC of 0.72 (95%CI:0.51-0.92). The best radiomic model was a GLM model and achieved an AUC of 0.71 (95%CI:0.58-0.84).ConclusionsOur CT-based lung radiomic models showed moderate to good performance at predicting CIP. We demonstrated the potential role of machine learning models associating clinical parameters and lung CT radiomic features to better identify patients treated with ICIs at risk of developing CIP.Advances in knowledge: Radiomics analysis of the lung parenchyma could be used as a non-invasive tool to select patients at risk of developing immune-checkpoint pneumonitis.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251344004"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study. 聚乙二醇脂质体阿霉素联合阿糖胞苷和粒细胞集落刺激因子治疗新诊断的老年和不适合急性髓系白血病患者：一项前瞻性、单中心、单组、II期研究

IF 2.7 4区医学

Technology in Cancer Research & Treatment Pub Date : 2025-01-01 Epub Date: 2025-03-27 DOI: 10.1177/15330338241312436

Bingqing Luo, Xiaoyan Tan, Yanfang Zhang, Xiao Hu, Hanqing Zeng, Hongbo Xiao, Shifeng Lou, Kang Zhou

{"title":"Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study.","authors":"Bingqing Luo, Xiaoyan Tan, Yanfang Zhang, Xiao Hu, Hanqing Zeng, Hongbo Xiao, Shifeng Lou, Kang Zhou","doi":"10.1177/15330338241312436","DOIUrl":"10.1177/15330338241312436","url":null,"abstract":"BackgroundEffective treatment options are limited for elderly patients with acute myeloid leukemia (AML). A prospective phase II study was conducted to investigate the safety and efficacy of pegylated liposomal doxorubicin (PLD) combined with low-dose cytarabine (LDAC) and granulocyte colony-stimulating factor (G-CSF) in newly diagnosed older and unfit AML patients.MethodsTwenty-two patients were enrolled and deemed evaluable. The study included one cycle of induction and four cycles of consolidation, followed by maintenance therapy.ResultsThe median age of enrolled patients was 71.5 years (range, 63 to 82 years), and 16 patients (72.7%) were over 70 years of age. The overall response rate (ORR) was 77.3% (n = 17) and the complete remission (CR)/complete remission with incomplete recovery (CRi) rate was 63.6% (n = 14) after the first induction cycle. With a median follow-up of 12.4 months, eight patients (57.1%) relapsed, with a median time to relapse of 12.3 months. The median duration of response (DOR) was 11.9 months (95% CI, 6.4 to NA months), the median overall survival (OS) was 15 months (95% CI, 8.4 to 21.6 months), and the median progression-free survival (PFS) was 7.5 months (95% CI, 4.6 to 15.1 months). Common grade 3 or greater adverse events included febrile neutropenia (77.8%) and infection (63.6%), with pneumonia being the most common (10, 45.5%). There was one death (4.5%) within 30 days.ConclusionThe combination of PLD, LDAC, and G-CSF is well-tolerated and exhibits high rates of CR/CRi and low early mortality, providing an attractive treatment option for newly diagnosed elderly and unfit AML patients.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241312436"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0